TCBIR/CD320: a potential therapeutic target upregulated in endothelial cells and associated with immune cell infiltration in liver hepatocellular carcinoma

Zhang, Shubin1,2,3; Jiang, Zhongyi1,2,3; Wang, Pusen1,2,3; Jiang, Weihao3; Ding, Wei1; Zhong, Lin1,2,3

2024-07-02

10.1007/s12672-024-01122-w

DISCOVER ONCOLOGY   影响因子和分区

2730-6011

CD320, which is a transmembrane protein responsible for facilitating the absorption of vitamin B12, plays a key role in this process. However, the relationships between CD320 and immune cell infiltration levels remain unclear, with limited studies investigating the diagnostic and prognostic significance of CD320 in hepatocellular carcinoma. We used various databases, including the TIMER, GEPIA, UALCAN and TCGA databases to investigate the expression levels of CD320 in hepatocellular carcinoma. Subsequently, we analyzed the prognosis of hepatocellular carcinoma patients with different expression levels of CD320. Furthermore, we also performed Western blot, immunohistochemistry, and immunofluorescence analyses to validate the results of the database analysis. Finally, the functions of CD320 in hepatocellular carcinoma were also confirmed via relevant cell experiments and angiogenesis assays. We found that CD320 expression was significantly upregulated in tumor vascular endothelial cells. Moreover, the knockdown of CD320 led to a reduction in angiogenesis in endothelial cells. Increased expression of CD320 was also correlated with a poor prognosis in patients with hepatocellular carcinoma, which suggested that CD320 may be a potential prognostic marker. Finally, TIMER analysis demonstrated that the infiltration of six immune cell types was significantly associated with high expression levels of CD320 in hepatocellular carcinoma. Herein, we demonstrated that CD320 may play an important role in angiogenesis in hepatocellular carcinoma. These findings suggested that CD320 may be a potential clinical prognostic marker and immunotherapy target for hepatocellular carcinoma.

TCBIR/CD320(1) Liver hepatocellular carcinoma(2) Prognostic biomarker(3) Immune Infiltration(4) Tumor angiogenesis(5)

SCI

英语

通讯

National Key Research and Development Program of China[2022YFC2304700] ; National Natural Science Foundation of China[82070672] ; Science and Technology Commission of Shanghai Municipality["20ZR1445500","20S31904800"] ; Three-year Action Plan for Clinical Skills and Clinical Innovation in Shanghai-level Hospitals[SHDC2020CR3035B]

Oncology ; Endocrinology & Metabolism

Oncology ; Endocrinology & Metabolism

WOS:001261440300003

SPRINGER

Web of Science

1.Shandong Second Med Univ, Affiliated Hosp 1, Weifang Peoples Hosp, Sch Clin Med,Dept Hepatobiliary & Pancreat Surg, 151 Guangwen St, Weifang 261041, Shandong, Peoples R China
2.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Dept Gen Surg, Hosp Affiliated 2, Shenzhen, Guangdong, Peoples R China
3.Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, Shanghai, Peoples R China

Zhang, Shubin,Jiang, Zhongyi,Wang, Pusen,et al. TCBIR/CD320: a potential therapeutic target upregulated in endothelial cells and associated with immune cell infiltration in liver hepatocellular carcinoma[J]. DISCOVER ONCOLOGY,2024,15(1).

Zhang, Shubin,Jiang, Zhongyi,Wang, Pusen,Jiang, Weihao,Ding, Wei,&Zhong, Lin.(2024).TCBIR/CD320: a potential therapeutic target upregulated in endothelial cells and associated with immune cell infiltration in liver hepatocellular carcinoma.DISCOVER ONCOLOGY,15(1).

Zhang, Shubin,et al."TCBIR/CD320: a potential therapeutic target upregulated in endothelial cells and associated with immune cell infiltration in liver hepatocellular carcinoma".DISCOVER ONCOLOGY 15.1(2024).